Chemo for Early-Stage Prostate Cancer? RTOG 0521 Says Maybe Chemo for Early-Stage Prostate Cancer? RTOG 0521 Says Maybe
In major clinical trial, docetaxel, which is typically used in metastatic disease, improved outcomes in high-risk, early-stage disease. However, the survival results fell short of the trial target.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Adding docetaxel-based chemotherapy to standard treatment for high-risk prostate cancer
(NRG Oncology) Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2019 Category: Cancer & Oncology Source Type: news
Adding Docetaxel to ADT for High-Risk Nonmetastatic Prostate Cancer: Does It Help?
Researchers tested the combination of docetaxel and ADT in a phase III randomized trial of patients with high-risk nonmetastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
No Benefit With Adjuvant Docetaxel in Nonmetastatic Prostate Cancer (CME/CE)
(MedPage Today) -- ADT with or without docetaxel yielded similar PFS at 10 years in androgen-dependent disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 5, 2019 Category: Hematology Source Type: news
Adjuvant Docetaxel No Help in High-Risk Prostate Cancer
(MedPage Today) -- Similar rates of progression at 10 years in androgen-dependent disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 31, 2019 Category: Hematology Source Type: news
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
This review of data from 9 RCTs (n=8,820) found a longer median overall survival for black men vs white men (21.0 vs 21.2 months, multivariable HR 0.81, 95% CI 0.72-0.91). The mechanism for this difference was unknown. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 9, 2019 Category: Consumer Health News Source Type: news
VARGADO data
Vargatef ® plus docetaxel could be an option after failure of immunotherapy in lung cancerResults from a real-world study1 support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2018 Category: Research Source Type: news
Taxotere (Docetaxel for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 19, 2018 Category: Drugs & Pharmacology Source Type: news
What Role Will Avelumab Play in Lung Cancer?
Avelumab did not improve overall survival compared with docetaxel in patients with PD-L1 –positive non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Nivolumab Is China ’s First Approved Immuno-Oncology Drug
In CheckMate -078, nivolumab yielded superior OS compared with docetaxel in previously treated NSCLC, regardless of PD-L1 expression and tumor histology. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
$200K Saved With First-Line Docetaxel for Prostate Cancer $200K Saved With First-Line Docetaxel for Prostate Cancer
For the first time, there is a cost-effectiveness study on two systemic drugs used in the treatment of newly diagnosed metastatic prostate cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Adjuvant Docetaxel Fails in Higher-Risk Prostate Ca
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
No DFS Benefit: Adjuvant Docetaxel in Higher-Risk Prostate Ca
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
First-Line Treatment of Hormone-Sensitive Metastatic PCa First-Line Treatment of Hormone-Sensitive Metastatic PCa
In addition to standard ADT, which patients with hormone-sensitive metastatic prostate cancer should receive abiraterone, docetaxel, both, or neither?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
